Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions (Q37876951)

24 August 2017

1 reference

title

Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions (English)

1 reference

24 August 2017

E Epailly

1

1 reference

24 August 2017

J Albanell

2

1 reference

24 August 2017

A Andreassen

3

1 reference

24 August 2017

C Bara

4

1 reference

24 August 2017

J M Campistol

5

1 reference

24 August 2017

J F Delgado

6

1 reference

24 August 2017

H Eisen

7

1 reference

24 August 2017

A E Fiane

8

1 reference

24 August 2017

P Mohacsi

9

1 reference

24 August 2017

S Schubert

10

1 reference

24 August 2017

L Sebbag

11

1 reference

24 August 2017

F M Turazza

12

1 reference

24 August 2017

H Valantine

13

1 reference

24 August 2017

A Zuckermann

14

1 reference

24 August 2017

L Potena

15

1 reference

24 August 2017

language of work or name

1 reference

18 May 2011

1 reference

24 August 2017

published in

Clinical Transplantation

1 reference

24 August 2017

volume

25

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

E475-86

1 reference

Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Post-transplant de novo malignancies in renal transplant recipients: the past and present

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Immunosuppressive drugs and the risk of cancer after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Azathioprine and UVA light generate mutagenic oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Etiologic agents of diarrhea in solid organ recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Immunosuppression for heart transplantation: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Calcineurin-inhibitor minimization protocols in heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Malignancies in renal transplantation: an unmet medical need

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Minimizing the risk of posttransplant malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Heart transplantation in children: indications. Report of the Ad Hoc Subcommittee of the Pediatric Committee of the American Society of Transplantation (AST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Malignancy after heart transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Predictive markers in breast and other cancers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

mTOR, cancer and transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Resistance to rapamycin: a novel anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Updates of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Targeting the mTOR signaling network in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

mTOR signalling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Recurrent Non-melanoma Skin Cancer: Remission of Field Cancerization after Conversion from Calcineurin Inhibitor- to Proliferation Signal Inhibitor-based Immunosuppression in a Cardiac Transplant Recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Nonmelanoma skin cancer and risk for subsequent malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Phase I study of everolimus in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Clinical recommendations for the use of everolimus in heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Minimization of immunosuppression: transplant immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Gene-expression profiling for rejection surveillance after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Clinical pharmacokinetics of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Hormone therapy in men and risk of cardiac allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Cytomegalovirus in transplantation - challenging the status quo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2011.01476.X

10.1111/J.1399-0012.2011.01476.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference